A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
- 87 Downloads
The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1).
Patients with ≤ 2 prior chemotherapy regimens for advanced or metastatic disease or hormone receptor-positive patients with disease progression on prior hormonal therapies were randomized 1:1 to 21-day cycles of ruxolitinib (n = 76) or placebo (n = 73) plus capecitabine. The primary endpoint was overall survival (OS).
Baseline characteristics were well balanced between groups. For ruxolitinib plus capecitabine versus placebo plus capecitabine, median OS was 11.2 months versus 10.9 months (log-rank test P = 0.762); median progression-free survival (PFS) was 4.5 months versus 2.5 months (log-rank test P = 0.151); and overall response rate (ORR) was 28.9% versus 13.7% (Cochran–Mantel–Haenszel test P = 0.024), respectively. A more favorable change in health-related quality of life (HRQoL) was observed with ruxolitinib plus capecitabine versus placebo plus capecitabine. Both regimens were generally tolerable. A higher incidence of grade 3/4 anemia (25.4% vs 5.6%) and a lower incidence of grade 3/4 palmar–plantar erythrodysesthesia (1.4% vs 12.7%) occurred with ruxolitinib plus capecitabine versus placebo plus capecitabine.
The addition of ruxolitinib to capecitabine for patients with advanced breast cancer and high systemic inflammation was generally tolerable; ORR was numerically greater, a more favorable change in HRQoL was observed, but neither OS nor PFS was improved compared with placebo plus capecitabine.
KeywordsRuxolitinib Capecitabine Advanced HER2-negative Breast cancer Phase 2 Randomized study
We thank the patients, their families, and their caregivers for participating in the trial. Medical writing assistance was provided by Abigail Marmont, Evidence Scientific Solutions Inc., Wilmslow, UK, and funded by Incyte Corporation.
Compliance with ethical standards
Conflict of interest
RG and WJ are employees of Incyte Corporation. GK is a contractor for Incyte Corporation. AD has received research funding from Incyte (institutional). HSR received research funding from Incyte for this trial. JOS, CXM, PR, DAY, GSW, KK, RS, and SD have no financial relationship with Incyte.
The protocol and all amendments were reviewed and approved by qualified institutional review boards/independent ethics committees before enrollment of participants in the study at each site. This study was conducted in accordance with the ethical principles of Good Clinical Practice, according to the International Conference on Harmonisation Guidelines. All aspects of the ethics review were conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from each subject in writing before protocol-specific screening tests were performed.
- 1.American Cancer Society (2015) Breast cancer. facts & figures 2015–2016. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2015-2016.pdf. Accessed 20 Dec 2017
- 3.Caffarel MM, Zaragoza R, Pensa S, Li J, Green AR, Watson CJ (2012) Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis. Cell Death Differ 19:511–522. https://doi.org/10.1038/cdd.2011.122 CrossRefPubMedGoogle Scholar
- 10.Jhaveri K, Teplinsky E, Silvera D et al (2016) Hyperactivated mTOR and JAK2/STAT3 pathways: molecular drivers and potential therapeutic targets of inflammatory and invasive ductal breast cancers after neoadjuvant chemotherapy. Clin Breast Cancer 16(113–122):e111. https://doi.org/10.1016/j.clbc.2015.11.006 Google Scholar
- 12.Quintás-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109–3117. https://doi.org/10.1182/blood-2009-04-214957 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.JAKAFI® (2017) (ruxolitinib) tablets [package insert]. Incyte Corporation, Wilmington, DE, 2017. www.jakafi.com/pdf/prescribing-information.pdf. Accessed 20 Dec 2017
- 14.JAKAVI® (2017) (ruxolitinib) tablets [summary of product characteristics]. Novartis Europharm Limited, Camberley, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002464/WC500133223.pdf. Accessed 20 Dec 2017
- 15.XELODA® (2017) (capecitabine) tablets [package insert]. Genentech, South San Francisco, 2017. https://www.gene.com/download/pdf/xeloda_prescribing.pdf. Accessed 20 Dec 2017
- 18.Hurwitz HI, Uppal N, Wagner SA et al (2015) Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 33:4039–4047. https://doi.org/10.1200/JCO.2015.61.4578 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. https://doi.org/10.1200/JCO.2009.25.6529 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984 CrossRefPubMedGoogle Scholar
- 22.Guidance for Industry (2007) Clinical trial endpoints for the approval of cancer drugs and biologics. Food and Drug Administration (FDA). http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071590.pdf. Accessed 15 Feb 2018
- 24.Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS, McMillan DC (2007) Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer 96:891–895. https://doi.org/10.1038/sj.bjc.6603682 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Twelves C, Cortés J, O’Shaughnessy J et al (2017) Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: results from the randomised phase III BEACON trial. Eur J Cancer 76:205–215. https://doi.org/10.1016/j.ejca.2017.02.011 CrossRefPubMedGoogle Scholar